M. Nechaeva

1.5k total citations · 1 hit paper
17 papers, 401 citations indexed

About

M. Nechaeva is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, M. Nechaeva has authored 17 papers receiving a total of 401 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 12 papers in Pulmonary and Respiratory Medicine and 5 papers in Cancer Research. Recurrent topics in M. Nechaeva's work include Advanced Breast Cancer Therapies (6 papers), Cancer Immunotherapy and Biomarkers (6 papers) and Cancer Genomics and Diagnostics (5 papers). M. Nechaeva is often cited by papers focused on Advanced Breast Cancer Therapies (6 papers), Cancer Immunotherapy and Biomarkers (6 papers) and Cancer Genomics and Diagnostics (5 papers). M. Nechaeva collaborates with scholars based in Russia, United States and Japan. M. Nechaeva's co-authors include Hiroji Iwata, Peter Schmid, Andreas Schneeweiß, Véronique Dièras, Sherene Loi, Luciana Molinero, Sylvia Adams, Amreen Husain, Carlos H. Barrios and Jane Yuet Ching Hui and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and JNCI Journal of the National Cancer Institute.

In The Last Decade

M. Nechaeva

17 papers receiving 399 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study

2021 205 citations Leisha A. Emens, Luciana Molinero et al. JNCI Journal of the National Cancer Institute profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
M. Nechaeva Russia	8	326	164	104	100	57	17	401
Zhongli Zhan China	11	178 0.5×	223 1.4×	62 0.6×	58 0.6×	78 1.4×	23	361
Yinde Huang China	6	156 0.5×	83 0.5×	150 1.4×	71 0.7×	99 1.7×	21	372
Fabio Scirocchi Italy	10	193 0.6×	83 0.5×	155 1.5×	87 0.9×	130 2.3×	15	395
Rin Ogiya Japan	8	228 0.7×	129 0.8×	74 0.7×	66 0.7×	47 0.8×	16	305
P. Scullin United Kingdom	4	153 0.5×	107 0.7×	118 1.1×	92 0.9×	105 1.8×	7	336
Nathan Tonlaar United States	6	179 0.5×	125 0.8×	154 1.5×	150 1.5×	117 2.1×	13	414
Linnéa La Fleur Sweden	6	219 0.7×	129 0.8×	206 2.0×	95 0.9×	161 2.8×	8	434
Liangliang Yang China	8	133 0.4×	89 0.5×	100 1.0×	208 2.1×	245 4.3×	10	436
Yusuke Shinchi Japan	10	141 0.4×	84 0.5×	112 1.1×	34 0.3×	81 1.4×	16	269
Teming Zhang China	6	160 0.5×	114 0.7×	110 1.1×	89 0.9×	135 2.4×	10	324

Countries citing papers authored by M. Nechaeva

Since Specialization

Citations

This map shows the geographic impact of M. Nechaeva's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Nechaeva with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Nechaeva more than expected).

Fields of papers citing papers by M. Nechaeva

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. Nechaeva. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Nechaeva. The network helps show where M. Nechaeva may publish in the future.

Co-authorship network of co-authors of M. Nechaeva

This figure shows the co-authorship network connecting the top 25 collaborators of M. Nechaeva. A scholar is included among the top collaborators of M. Nechaeva based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. Nechaeva. M. Nechaeva is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

Schmid, Peter, Heather L. McArthur, Baojun Xu, et al.. (2024). LBA19 Capivasertib (C) + paclitaxel (P) as first-line treatment of metastatic triple-negative breast cancer (mTNBC): The CAPItello-290 phase III trial. Annals of Oncology. 35. S1212–S1213. 5 indexed citations

Andabekov, Timur, Mikhail Dvorkin, Р. А. Зуков, et al.. (2023). Final results of a phase II trial of prolgolimab with platinum-based therapy and bevacizumab in patients with advanced cervical cancer.. Journal of Clinical Oncology. 41(16_suppl). 5536–5536. 2 indexed citations

Espósito, F., Sun Young Rha, Marc Van den Eynde, et al.. (2022). 1261TiP CARMEN-GC01: Phase II, open-label, single-arm study of tusamitamab ravtansine in combination with ramucirumab in pretreated patients with gastric or gastroesophageal junction adenocarcinoma (GA/GEJA). Annals of Oncology. 33. S1124–S1124. 2 indexed citations

Makharadze, Tamta, Ruben G.W. Quek, Tamar Melkadze, et al.. (2021). 93P Patient-reported outcomes (PROs) with cemiplimab or placebo plus platinum-doublet chemotherapy (chemo) for first-line (1L) treatment of advanced non-small cell lung cancer (aNSCLC): EMPOWER-Lung 3 trial. Annals of Oncology. 32. S1414–S1414. 1 indexed citations

Emens, Leisha A., Luciana Molinero, Sherene Loi, et al.. (2021). Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study. JNCI Journal of the National Cancer Institute. 113(8). 1005–1016. 205 indexed citations breakdown →

Gogishvili, Miranda, Tamar Melkadze, Tamta Makharadze, et al.. (2021). LBA51 EMPOWER-Lung 3: Cemiplimab in combination with platinum doublet chemotherapy for first-line (1L) treatment of advanced non-small cell lung cancer (NSCLC). Annals of Oncology. 32. S1328–S1328. 11 indexed citations

Kristeleit, Rebecca, Alla Lisyanskaya, А. А. Феденко, et al.. (2021). O009/#786 Rucaparib vs chemotherapy in patients with advanced, relapsed ovarian cancer and a deleterious brca mutation: efficacy and safety from ariel4, a randomized phase 3 study. A5–A6. 3 indexed citations

Emens, Leisha A., Luciana Molinero, Sylvia Adams, et al.. (2020). 296P Tumour mutational burden and clinical outcomes with first-line atezolizumab and nab-paclitaxel in triple-negative breast cancer: Exploratory analysis of the phase III IMpassion130 trial. Annals of Oncology. 31. S360–S361. 23 indexed citations

Schmid, Peter, Javier Cortés, Mark E. Robson, et al.. (2020). A phase III trial of capivasertib and paclitaxel in first-line treatment of patients with metastatic triple-negative breast cancer (CAPItello290).. Journal of Clinical Oncology. 38(15_suppl). TPS1109–TPS1109. 12 indexed citations

10.

Schmid, Peter, Javier Cortés, Mark E. Robson, et al.. (2020). Abstract OT2-08-02: Capivasertib and paclitaxel in first-line treatment of patients with metastatic triple-negative breast cancer: A phase III trial (CAPItello-290). Cancer Research. 80(4_Supplement). OT2–8. 7 indexed citations

11.

Tjulandin, Sergei, М. Yu. Fedyanin, Lev Demidov, et al.. (2019). Final Results of Phase II Trial (MIRACULUM) of the Novel PD-1 Inhibitor Prolgolimab in Patients with Advanced Melanoma. Annals of Oncology. 30. xi44–xi44. 5 indexed citations

12.

Loi, Sherene, HS Rugo, Andreas Schneeweiß, et al.. (2019). Abstract GS1-04: IMpassion130: Efficacy in immune biomarker subgroups from the global, randomized, double-blind, placebo-controlled, phase III study of atezolizumab + nab-paclitaxel in patients with treatment-naïve, locally advanced or metastatic triple-negative breast cancer. Cancer Research. 79(4_Supplement). GS1–4. 60 indexed citations

13.

Schüler, Martin, S-E. Al-Batran, Zanete Zvirbule, et al.. (2016). Final results of the FAST study, an international, multicenter, randomized, phase II trial of epirubicin, oxaliplatin, and capecitabine (EOX) with or without the anti-CLDN18.2 antibody IMAB362 as first-line therapy in patients with advanced CLDN18.2+ gastric and gastroesophageal junction (GEJ) adenocarcinoma. Annals of Oncology. 27. vi208–vi208. 18 indexed citations

14.

Lordick, Florian, Martin Schüler, S-E. Al-Batran, et al.. (2016). 220O Claudin 18.2 - a novel treatment target in the multicenter, randomized, phase II FAST study, a trial of epirubicin, oxaliplatin, and capecitabine (EOX) with or without the anti-CLDN18.2 antibody IMAB362 as 1st line therapy in advanced gastric and gastroesophageal junction (GEJ) cancer. Annals of Oncology. 27. ix69–ix69. 2 indexed citations

15.

Al‐Batran, Salah‐Eddin, Martin Schüler, Zanete Zvirbule, et al.. (2016). FAST: An international, multicenter, randomized, phase II trial of epirubicin, oxaliplatin, and capecitabine (EOX) with or without IMAB362, a first-in-class anti-CLDN18.2 antibody, as first-line therapy in patients with advanced CLDN18.2+ gastric and gastroesophageal junction (GEJ) adenocarcinoma.. Journal of Clinical Oncology. 34(18_suppl). 35 indexed citations

16.

Al-Batran, Salah-Eddin, Martin Schüler, Zanete Zvirbule, et al.. (2016). FAST: An international, multicenter, randomized, phase II trial of epirubicin, oxaliplatin, and capecitabine (EOX) with or without IMAB362, a first-in-class anti-CLDN18.2 antibody, as first-line therapy in patients with advanced CLDN18.2+ gastric and gastroesophageal junction (GEJ) adenocarcinoma.. Journal of Clinical Oncology. 34(15_suppl). LBA4001–LBA4001. 9 indexed citations

17.

Krivorotko, Petr, et al.. (2015). Efficacy and safety of extimia® (empegfilgrastim): results of a double-blind controlled phase iii study in patients with diagnosis «breast cancer» receiving myelosuppressive chemotherapy. SHILAP Revista de lepidopterología. 17(2). 45–52. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact